It was recently shown that treating pancreatic ductal carcinoma cells with 5-aza-dC leads to increased expression of HAS2, suggesting an epigenetic mechanism is involved in regulating HAS2 in cancer cells [43]. Here, HAS2 is linked to pancreatic ductal adenocarcinoma.